| Comprehensive functional analysis of N-linked glycans on Ebola virus GP1 NJ Lennemann, BA Rhein, E Ndungo, K Chandran, X Qiu, W Maury MBio 5 (1), 10.1128/mbio. 00862-13, 2014 | 112 | 2014 |
| Interferon-γ inhibits Ebola virus infection BA Rhein, LS Powers, K Rogers, M Anantpadma, BK Singh, Y Sakurai, ... PLoS pathogens 11 (11), e1005263, 2015 | 98 | 2015 |
| Enhancement of respiratory mucosal antiviral defenses by the oxidation of iodide AJ Fischer, NJ Lennemann, S Krishnamurthy, P Pócza, L Durairaj, ... American journal of respiratory cell and molecular biology 45 (4), 874-881, 2011 | 90 | 2011 |
| TIM1 (HAVCR1) is not essential for cellular entry of either quasi-enveloped or naked hepatitis A virions A Das, A Hirai-Yuki, O González-López, B Rhein, S Moller-Tank, ... MBio 8 (5), 10.1128/mbio. 00969-17, 2017 | 68 | 2017 |
| TIM-1 serves as a receptor for Ebola virus in vivo, enhancing viremia and pathogenesis B Brunton, K Rogers, EK Phillips, RB Brouillette, R Bouls, NS Butler, ... PLoS neglected tropical diseases 13 (6), e0006983, 2019 | 57 | 2019 |
| Ebola virus entry into host cells: identifying therapeutic strategies BA Rhein, WJ Maury Current clinical microbiology reports 2, 115-124, 2015 | 46 | 2015 |
| Characterization of human and murine T-cell immunoglobulin mucin domain 4 (TIM-4) IgV domain residues critical for Ebola virus entry BA Rhein, RB Brouillette, GA Schaack, JA Chiorini, W Maury Journal of virology 90 (13), 6097-6111, 2016 | 39 | 2016 |
| IL-4/IL-13 polarization of macrophages enhances Ebola virus glycoprotein-dependent infection KJ Rogers, B Brunton, L Mallinger, D Bohan, KM Sevcik, J Chen, ... PLoS neglected tropical diseases 13 (12), e0007819, 2019 | 36 | 2019 |
| Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma J Cook, KW Peng, TE Witzig, SM Broski, JC Villasboas, J Paludo, ... Blood Advances 6 (11), 3268-3279, 2022 | 31 | 2022 |
| Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, noninfectious vaccine against Ebola virus challenge in mice NJ Lennemann, AS Herbert, R Brouillette, B Rhein, RA Bakken, ... Journal of virology 91 (17), 10.1128/jvi. 00479-17, 2017 | 29 | 2017 |
| IMMUNO-COV v2. 0: Development and validation of a high-throughput clinical assay for measuring SARS-CoV-2-neutralizing antibody titers R Vandergaast, T Carey, S Reiter, C Lathrum, P Lech, C Gnanadurai, ... MSphere 6 (3), 10.1128/msphere. 00170-21, 2021 | 18 | 2021 |
| Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2 R Vandergaast, T Carey, S Reiter, P Lech, C Gnanadurai, M Tesfay, ... Biorxiv, 2020.05. 26.117549, 2020 | 17 | 2020 |
| Frontline Science: CD40 signaling restricts RNA virus replication in Mϕs, leading to rapid innate immune control of acute virus infection KJ Rogers, O Shtanko, LL Stunz, LN Mallinger, T Arkee, ME Schmidt, ... Journal of Leucocyte Biology 109 (2), 309-325, 2021 | 10 | 2021 |
| Clinical activity of systemic VSV-IFNβ-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma. J Cook, KW Peng, SM Geyer, BF Ginos, AC Dueck, N Packiriswamy, ... Journal of Clinical Oncology 39 (15_suppl), 2500-2500, 2021 | 7 | 2021 |
| IMMUNO-COV v2. 0: development and validation of a high-throughput clinical assay for measuring SARS-CoV-2-neutralizing antibody titers. mSphere 6: e0017021 R Vandergaast, T Carey, S Reiter, C Lathrum, P Lech, C Gnanadurai, ... | 7 | 2021 |
| New transgenic NIS reporter rats for longitudinal tracking of fibrogenesis by high-resolution imaging B Brunton, L Suksanpaisan, H Li, Q Liu, Y Yu, A Vrieze, L Zhang, N Jenks, ... Scientific reports 8 (1), 14209, 2018 | 5 | 2018 |
| Abstract P6-21-03: Phase I trial of intratumoral (IT) administration of a NIS-expressing derivative manufactured from a genetically engineered strain of measles virus (MV) MC Liu, KW Peng, MJ Federspiel, SJ Russell, BA Brunton, Y Zhou, ... Cancer Research 79 (4_Supplement), P6-21-03-P6-21-03, 2019 | 4 | 2019 |
| Abstract CT072: First in human (FIH) dose escalation studies of intravenous administration of VSV-IFNβ-NIS (Voyager-V1™) in Stage IV or recurrent endometrial cancer J Bakkum-Gamez, MS Block, N Packiriswamy, BA Brunton, U Deepak, ... Cancer Research 78 (13_Supplement), CT072-CT072, 2018 | 3 | 2018 |
| TCL-461: clinical activity of systemic VSV-IFNβ-NIS oncolytic virotherapy in patients with relapsed refractory hematologic malignancies J Cook, KW Peng, S Geyer, AC Dueck, BF Ginos, M Giers, ... Clinical Lymphoma Myeloma and Leukemia 21, S416-S417, 2021 | 2 | 2021 |
| Phase I trial of systemic administration of vesicular stomatitis virus genetically engineered to express NIS and human interferon beta, in patients with relapsed or refractory … J Cook, KW Peng, BF Ginos, AC Dueck, M Giers, N Packiriswamy, ... Blood 136, 7-8, 2020 | 2 | 2020 |
Wendy MauryDepartment of microbiology, university of iowa
Wendy MauryDepartment of microbiology, university of iowa